febuxostat has been researched along with triazoles in 23 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (triazoles) | Trials (triazoles) | Recent Studies (post-2010) (triazoles) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 25,808 | 2,252 | 13,501 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (78.26) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Hussar, DA | 1 |
| Baumgartner, S; Fleischmann, R; Hingorani, V; Kerr, B; Manhard, K; Miner, JN; Polvent, E; Quart, B; Shen, Z; Suster, M; Yeh, LT | 1 |
| Edwards, NL; So, A | 1 |
| Jansen, TL | 1 |
| Deeks, ED | 1 |
| Adler, S; Baumgartner, S; Bhakta, N; Dalbeth, N; Fung, M; Jones, G; Khanna, D; Kopicko, J; Perez-Ruiz, F; Storgard, C; Terkeltaub, R | 1 |
| Hill-McManus, D; Hughes, D; Lane, S; Marshall, S; Soto, E | 2 |
| Aksenov, S; Eriksson, UG; Peck, CC; Stanski, DR | 1 |
| Kuehn, BM | 1 |
| Basile, M; Cicchetti, A; Drago, C; Rolli, FR; Ruggeri, M | 1 |
| Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X | 1 |
| Jansen, TL; Perez-Ruiz, F; Richette, P; Tausche, AK | 1 |
| Robinson, PC | 1 |
| Fields, TR | 1 |
| Baumgartner, S; Dalbeth, N; Fung, M; Jones, G; Khanna, D; Perez-Ruiz, F; Terkeltaub, R | 1 |
| Gupta, MK; Singh, JA | 1 |
| Oyagüez, I; Pérez-Ruiz, F; Presa, M | 1 |
| Desai, RJ; Kim, E; Kim, SC; Lii, J; Neogi, T | 1 |
| Borghi, C; Cicero, AFG; Fogacci, F; Kuwabara, M | 1 |
| Abdel Hakiem, AF; Abdel-Megied, AM; Belal, F; Magdy, G | 1 |
| Bombardier, C; Edwards, CJ; Pardo Pardo, J; Sriranganathan, MK; Vinik, O | 1 |
| Cheng, H; Hou, X; Li, X; Nan, G; Ren, L; Tian, J; Xiao, Z; Yan, D; Yang, Y; Ye, F | 1 |
8 review(s) available for febuxostat and triazoles
| Article | Year |
|---|---|
Emerging therapies for gout.
Topics: Acetamides; Adrenocorticotropic Hormone; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Benzodiazepines; Febuxostat; Gout; Gout Suppressants; Humans; Imino Furanoses; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Melanocortins; Phenylacetates; Polyethylene Glycols; Pyrimidinones; Recombinant Fusion Proteins; Thiazoles; Thioglycolates; Triazoles; Urate Oxidase; Uricosuric Agents | 2014 |
Lesinurad: A Review in Hyperuricaemia of Gout.
Topics: Adult; Allopurinol; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Kidney; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2017 |
International position paper on the appropriate use of uricosurics with the introduction of lesinurad.
Topics: Benzbromarone; Europe; Febuxostat; Gout; Humans; International Cooperation; Practice Guidelines as Topic; Probenecid; Rheumatology; Thioglycolates; Triazoles; Uricosuric Agents; Xanthine Oxidase | 2018 |
Gout - An update of aetiology, genetics, co-morbidities and management.
Topics: Allopurinol; Chronic Disease; Comorbidity; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thioglycolates; Triazoles; Uric Acid | 2018 |
The Challenges of Approaching and Managing Gout.
Topics: Acetamides; Allopurinol; Antibodies, Monoclonal, Humanized; Colchicine; Diet Therapy; Febuxostat; Gout; Gout Suppressants; Humans; Medication Adherence; Patient Education as Topic; Phenylacetates; Polyethylene Glycols; Quality of Health Care; Rheumatology; Thioglycolates; Triazoles; Urate Oxidase; Uric Acid | 2019 |
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Topics: Allopurinol; Anti-Inflammatory Agents; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid | 2019 |
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.
Topics: Acetamides; Allopurinol; Benzbromarone; Chronic Disease; Evidence-Based Medicine; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Naphthalenes; Nitriles; Phenylacetates; Polyethylene Glycols; Probenecid; Propionates; Pyridines; Thioglycolates; Triazoles; Urate Oxidase; Uricosuric Agents; Xanthine Oxidase | 2021 |
Interventions for tophi in gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Randomized Controlled Trials as Topic; Thioglycolates; Triazoles; Urate Oxidase | 2021 |
4 trial(s) available for febuxostat and triazoles
| Article | Year |
|---|---|
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Topics: Adult; Aged; Colchicine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Thioglycolates; Triazoles; Uric Acid | 2014 |
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
Topics: Creatinine; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid | 2017 |
Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Topics: Administration, Oral; Adult; Aged; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Thioglycolates; Time Factors; Treatment Outcome; Triazoles; Uric Acid; Uricosuric Agents; Young Adult | 2018 |
Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.
Topics: Adult; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thioglycolates; Treatment Outcome; Triazoles; Uricosuric Agents | 2019 |
11 other study(ies) available for febuxostat and triazoles
| Article | Year |
|---|---|
New Drugs2010, PART 1.
Topics: Acetamides; Antibodies, Monoclonal; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Azepines; Benzazepines; Benzhydryl Compounds; Benzyl Alcohol; Benzylamines; Cyclams; Cyclopropanes; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Ethanolamines; Everolimus; Febuxostat; Fluorenes; Fluoroquinolones; Gout Suppressants; Heterocyclic Compounds; Humans; Immunosuppressive Agents; Indoles; Lacosamide; Milnacipran; Oligopeptides; Phenols; Selective Serotonin Reuptake Inhibitors; Sirolimus; Tapentadol; Thiazoles; Tolvaptan; Triazoles | 2010 |
Treat to target in gout by combining two modes of action.
Topics: Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thiazoles; Thioglycolates; Triazoles | 2014 |
Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.
Topics: Computer Simulation; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Models, Biological; Risk Assessment; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid; Xanthine Oxidase | 2018 |
Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Humans; Hyperuricemia; Models, Theoretical; Precision Medicine; Thioglycolates; Triazoles; Uric Acid; Uricosuric Agents | 2018 |
Chronic Disease Approaches Needed to Curb Gout's Growing Burden.
Topics: Allopurinol; Chronic Disease; Diet; Drug Combinations; Febuxostat; Gout; Gout Suppressants; Healthy Lifestyle; Humans; Patient Education as Topic; Practice Guidelines as Topic; Purines; Thioglycolates; Triazoles; Uric Acid | 2018 |
Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
Topics: Allopurinol; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Thioglycolates; Triazoles | 2018 |
Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
Topics: Allopurinol; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Febuxostat; Gout; Gout Suppressants; Health Care Costs; Humans; Medication Adherence; Models, Biological; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Thioglycolates; Treatment Outcome; Triazoles; United Kingdom; Uric Acid | 2018 |
Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
Topics: Allopurinol; Cost-Benefit Analysis; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Markov Chains; Spain; Thioglycolates; Triazoles | 2019 |
Trends in Utilization of Urate-Lowering Therapies Following the US Food and Drug Administration's Boxed Warning on Febuxostat.
Topics: Allopurinol; Cardiovascular Diseases; Cause of Death; Drug Labeling; Febuxostat; Gout; Gout Suppressants; Humans; Mortality; Polyethylene Glycols; Practice Patterns, Physicians'; Probenecid; Risk Factors; Thioglycolates; Triazoles; United States; United States Food and Drug Administration; Urate Oxidase | 2021 |
A novel quality by design approach for development and validation of a green reversed-phase HPLC method with fluorescence detection for the simultaneous determination of lesinurad, febuxostat, and diflunisal: Application to human plasma.
Topics: Chromatography, High Pressure Liquid; Diflunisal; Equipment Design; Febuxostat; Fluorescence; Humans; Software; Tablets; Thioglycolates; Triazoles | 2021 |
Discovery of novel 1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors with hypouricemic effects.
Topics: Animals; Enzyme Inhibitors; Febuxostat; Gout; Hyperuricemia; Mice; Triazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2022 |